Treatment with 13-cis-retinoic acid in transfusion-dependent patients with myelodysplastic syndrome and decreased toxicity with addition of alpha-tocopherol
- 1 December 1990
- journal article
- research article
- Published by Elsevier in The American Journal of Medicine
- Vol. 89 (6) , 739-747
- https://doi.org/10.1016/0002-9343(90)90215-y
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Effects of Recombinant Human Granulocyte–Macrophage Colony-Stimulating Factor in Patients with Myelodysplastic SyndromesNew England Journal of Medicine, 1987
- A randomized trial of 13‐cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndromeBritish Journal of Haematology, 1987
- EFFECT OF 13-cis-RETINOIC ACID ON SURVIVAL OF PATIENTS WITH MYELODYSPLASTIC SYNDROMEThe Lancet, 1987
- Primary myelodysplastic syndrome: Treatment of 6 patients with 13‐cis retinoic acidScandinavian Journal of Haematology, 1986
- Cytogenetics of the myelodysplastic syndromesScandinavian Journal of Haematology, 1986
- Preleukaemia: A long‐term prospective study of 326 patientsScandinavian Journal of Haematology, 1986
- Proposals for the classification of the myelodysplastic syndromesBritish Journal of Haematology, 1982
- A RAPID BANDING TECHNIQUE FOR HUMAN CHROMOSOMESThe Lancet, 1971
- The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agentJournal of Chronic Diseases, 1961
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958